NDC 73377-122-01 - Cromolyn sodium
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 73377-122
- Requested NDC
- 73377-122-01
- Package NDCs from labels
- 73377-122-01
- Manufacturer
- AX Pharmaceutical Corp
- Effective date
- 2021-04-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cromolyn sodium - AX Pharmaceutical Corp | AX Pharmaceutical Corp | 2021-04-05 | BULK INGREDIENT |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| NasalCrom | CROMOLYN SODIUM | Prestige Brands Holdings, Inc. | b34d36ca-4df4-458c-af0f-c0d0c9a025d9 | 2026-06-03 | Warnings | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | Preferred Pharmaceuticals Inc. | 18892411-465f-4d8d-9550-7dafa6c6a0a3 | 2026-04-01 | Adverse reactions | Q2WXR1I0PK |
| CROMOLYN SODIUM | CROMOLYN SODIUM | Omnivium Pharmaceuticals LLC | a742664b-265e-49f9-9744-d04e1fb620ae | 2026-01-13 | Warnings, Adverse reactions | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | Sandoz Inc | b32851c3-cd97-4be4-a09c-1deab1d6966b | 2025-02-20 | Adverse reactions | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | A-S Medication Solutions | 0d30fb0a-e343-426d-8203-5816bd4cec2f | 2024-11-07 | Adverse reactions | Q2WXR1I0PK |
| CROMOLYN SODIUM | CROMOLYN SODIUM | Micro Labs Limited | 93f80edb-3b38-423e-8cd6-5b5cb4393ec2 | 2024-09-26 | Warnings, Adverse reactions | Q2WXR1I0PK |
| Gastrocrom | CROMOLYN SODIUM | Viatris Specialty LLC | 00623958-a8fe-47d1-a0d2-0aa4e2f7966e | 2024-06-26 | Warnings, Adverse reactions | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | Teva Pharmaceuticals USA, Inc. | 8fe37a7a-edd6-4733-bb7e-e01c1906aeba | 2023-12-14 | Warnings, Adverse reactions | Q2WXR1I0PK |
| CROMOLYN SODIUM | CROMOLYN SODIUM | Rising Pharma Holdings, Inc. | 61c9cb85-129e-4490-b5f7-357307fcecbf | 2021-08-01 | Warnings, Adverse reactions | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | Bausch & Lomb Incorporated | 379f4b59-6866-4b5c-9b1b-d8a35b741461 | 2021-06-01 | Warnings | Q2WXR1I0PK |
| Cromolyn Sodium | CROMOLYN SODIUM | Proficient Rx LP | 34ef00e8-0c01-4225-9a40-822ab245752a | 2019-10-01 | Adverse reactions | Q2WXR1I0PK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.